Cabiralizumab
- Generic Name
- Cabiralizumab
- Drug Type
- Biotech
- CAS Number
- 1613144-80-1
- Unique Ingredient Identifier
- 5FJL6W0640
- Background
Cabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Procedure: Tumor biopsyProcedure: Bone marrowProcedure: Blood draw
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT04331067
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03927105
- Locations
- ๐บ๐ธ
Unviersity of Wisconsin, Madison, Wisconsin, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
๐บ๐ธOhio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
- Conditions
- Pancreatic Cancer Stage IV
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Hitendra Patel
- Target Recruit Count
- 2
- Registration Number
- NCT03697564
- Locations
- ๐บ๐ธ
UCSD Moores Cancer Center, La Jolla, California, United States
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
- Conditions
- Non-small Cell Lung CancerAdvanced MelanomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 42
- Registration Number
- NCT03502330
- Locations
- ๐บ๐ธ
Yale Cancer Center, New Haven, Connecticut, United States
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 60
- Registration Number
- NCT03431948
- Locations
- ๐บ๐ธ
University of Chicago Medical Center, Chicago, Illinois, United States
Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01962337
- Locations
- ๐ญ๐บ
Drug Research Center, Kaposvar, Hungary
๐ญ๐บPRA Clinical Unit, Budapest, Hungary
๐ต๐ฑMedPolina, Poznan, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.